Advanced Enzyme Technologies (ADVENZYMES) Aktienübersicht
Advanced Enzyme Technologies Limited ist zusammen mit seinen Tochtergesellschaften in der Forschung, Entwicklung, Herstellung und Vermarktung von Enzymen und Probiotika in Indien, Europa, den Vereinigten Staaten, Asien und international tätig. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 5/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 4/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für ADVENZYMES festgestellt.
ADVENZYMES Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Advanced Enzyme Technologies Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | ₹325.05 |
| 52-Wochen-Hoch | ₹419.00 |
| 52-Wochen-Tief | ₹251.95 |
| Beta | 0.69 |
| 1 Monat Veränderung | -11.80% |
| 3 Monate Veränderung | 5.74% |
| 1 Jahr Veränderung | -0.73% |
| 3 Jahre Veränderung | 7.61% |
| 5 Jahre Veränderung | -18.67% |
| Veränderung seit IPO | 18.19% |
Aktuelle Nachrichten und Updates
Recent updates
Impressive Earnings May Not Tell The Whole Story For Advanced Enzyme Technologies (NSE:ADVENZYMES)
Advanced Enzyme Technologies Limited's ( NSE:ADVENZYMES ) robust earnings report didn't manage to move the market for...If EPS Growth Is Important To You, Advanced Enzyme Technologies (NSE:ADVENZYMES) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
ADVENZYMES: Stable Case Balances Model Assumptions And Upcoming Dividend Decisions
Analysts have kept their ₹370 price target on Advanced Enzyme Technologies unchanged, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E that, in their view, broadly offset each other in the valuation model. Analyst Commentary Recent commentary on Advanced Enzyme Technologies highlights a mix of optimism about the company’s positioning and caution around execution and valuation assumptions, which feeds into how analysts are thinking about the ₹370 target.ADVENZYMES: Steady Cash Assumptions And Upcoming Board Decisions Will Shape Returns
Narrative update on Advanced Enzyme Technologies The analyst price target for Advanced Enzyme Technologies is held steady at ₹370, as analysts point to only very small adjustments in assumptions for discount rate, revenue growth, profit margin and forward P/E after reviewing recent research on comparable companies. Analyst Commentary Recent Street research on other mid-cap service companies has given analysts a reference point as they revisit models for Advanced Enzyme Technologies, even though those reports focus on a different stock.ADVENZYMES: Stable Margins And Refined Assumptions Will Guide Future Returns
Analysts kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, citing modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions rather than any change in their core outlook. Analyst Commentary Analysts keeping fair value at ₹370 are focusing on how well Advanced Enzyme Technologies can execute on its current plan rather than changing their fundamental view of the stock.ADVENZYMES: Steady Risk And Margins Will Support Future Upside
Analysts have kept their fair value estimate for Advanced Enzyme Technologies steady at ₹370. They cited updated assumptions around the discount rate, growth, margins and future P/E that reflect fine tuning of their models rather than a change in overall conviction.ADVENZYMES: Steady Assumptions And Risk Profile Will Support Future Upside
Analysts have kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, with only small adjustments to the discount rate, growth, margin and future P/E assumptions informing this unchanged price target. Analyst Commentary Bullish Takeaways Bullish analysts see support for the ₹370 fair value estimate from the decision to keep key model assumptions, such as growth and margins, broadly consistent rather than revising them sharply.ADVENZYMES: Refined Risk Assumptions And Stable Outlook Will Support Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370, making small changes to assumptions such as a slightly lower discount rate and marginally adjusted long-term growth and P/E inputs after revisiting their models. Analyst Commentary Bullish Takeaways Bullish analysts see the reaffirmed fair value of ₹370 as supported by refreshed assumptions, suggesting that the refined discount rate and long term inputs still back the existing valuation framework for Advanced Enzyme Technologies.ADVENZYMES: Free Cash Flow Momentum And Cleaner Portfolio Will Drive Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370.0 per share, while slightly adjusting assumptions on discount rate, growth, margins and future P/E to reflect updated free cash flow trends and a cleaner portfolio. They expect these factors to support improvement in the second half.ADVENZYMES: Stable Assumptions And Future P/E Reset Will Drive Upside
Analysts have kept their price target for Advanced Enzyme Technologies steady at ₹370, citing largely unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E in their updated models. What's in the News A board meeting is scheduled on January 31, 2026 to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).ADVENZYMES: Future P/E Reset Will Signal Upside Potential For Shares
Analysts have trimmed their fair value estimate for Advanced Enzyme Technologies from ₹440 to ₹370, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower future P/E multiple. What's in the News Board meeting scheduled for January 31, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Share Price Not Quite Adding Up
There wouldn't be many who think Advanced Enzyme Technologies Limited's ( NSE:ADVENZYMES ) price-to-earnings (or "P/E...Preventive Health And Green Chemistry Will Expand Future Markets
Key Takeaways Expansion into health, wellness, and sustainable enzymatic solutions, along with new B2C initiatives, positions for growth and improved margins as consumer demand rises. International diversification, R&D investment, and increased capacity utilization support long-term product differentiation, earnings stability, and operating leverage.Here's What's Concerning About Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Advanced Enzyme Technologies' (NSE:ADVENZYMES) Dividend Will Be ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Due To Pay A Dividend Of ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...Is Advanced Enzyme Technologies (NSE:ADVENZYMES) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar
Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) shareholders have had their patience rewarded with a 26% share...We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now
Key Insights Advanced Enzyme Technologies' Annual General Meeting to take place on 25th of July Salary of ₹6.69m is...Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.00...Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Aktionärsrenditen
| ADVENZYMES | IN Chemicals | IN Markt | |
|---|---|---|---|
| 7D | 0.2% | 2.1% | 0.8% |
| 1Y | -0.7% | -4.4% | -1.2% |
Rendite im Vergleich zur Industrie: ADVENZYMES übertraf die Branche Indian Chemicals , die im vergangenen Jahr eine Rendite von -4.4 erzielte.
Rendite vs. Markt: ADVENZYMES entspricht dem Indian Markt, der im vergangenen Jahr eine Rendite von -1.2 erzielte.
Preisvolatilität
| ADVENZYMES volatility | |
|---|---|
| ADVENZYMES Average Weekly Movement | 6.5% |
| Chemicals Industry Average Movement | 6.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 3.8% |
Stabiler Aktienkurs: ADVENZYMES hatte in den letzten 3 Monaten im Vergleich zum Indian -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: ADVENZYMESDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1957 | 409 | n/a | www.advancedenzymes.com |
Advanced Enzyme Technologies Limited ist zusammen mit seinen Tochtergesellschaften in der Forschung, Entwicklung, Herstellung und Vermarktung von Enzymen und Probiotika in Indien, Europa, den Vereinigten Staaten, Asien und international tätig. Das Unternehmen bietet Enzyme und Nahrungsergänzungsmittel auf Probiotikabasis für die menschliche Gesundheit und die Tierernährung, die Obst- und Gemüseverarbeitung, das Backen, Brauen und Mälzen, die Stärke- und Getreideverarbeitung, die Proteinmodifikation, die Hefeverarbeitung, die Milch- und Käseverarbeitung und die Verarbeitung von Ölen und Fetten sowie für Spezialanwendungen, Biokraftstoffe und Biokatalyse. Das Unternehmen bietet Enzyme für die Non-Food-Verarbeitung in der Textil-, Leder-, Zellstoff- und Papierverarbeitung sowie Wasch- und Reinigungsmittel an.
Advanced Enzyme Technologies Limited's Grundlagenzusammenfassung
| ADVENZYMES grundlegende Statistiken | |
|---|---|
| Marktanteil | ₹36.40b |
| Gewinn(TTM) | ₹1.69b |
| Umsatz(TTM) | ₹7.46b |
Ist ADVENZYMES zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| ADVENZYMES Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | ₹7.46b |
| Kosten der Einnahmen | ₹2.07b |
| Bruttogewinn | ₹5.38b |
| Sonstige Ausgaben | ₹3.70b |
| Gewinn | ₹1.69b |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
Aug 14, 2026
| Gewinn per Aktie (EPS) | 15.07 |
| Bruttomarge | 72.20% |
| Nettogewinnspanne | 22.62% |
| Schulden/Eigenkapital-Verhältnis | 1.2% |
Wie hat sich ADVENZYMES auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
Zahlt ADVENZYMES eine zuverlässige Dividende?
Siehe ADVENZYMES Dividendenhistorie und Benchmarks| Advanced Enzyme Technologies Dividendentermine | |
|---|---|
| Ex-Dividenden Datum | Jul 24 2026 |
| Datum der Dividendenzahlung | Aug 30 2026 |
| Tage bis Ex-Dividende | 7 days |
| Tage bis zum Datum der Dividendenzahlung | 44 days |
Zahlt ADVENZYMES eine zuverlässige Dividende?
Siehe ADVENZYMES Dividendenhistorie und BenchmarksUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/16 10:03 |
| Aktienkurs zum Tagesende | 2026/07/16 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Advanced Enzyme Technologies Limited wird von 4 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Nandan Chakraborty | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| null null | DBS Bank Ltd |